Voyager Therapeutics, Inc. (VYGR) Current Ratio
- Current ratio · latest quarter: Value 7.51×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 7.51× | Current assets / current liabilities. $125.23M ÷ $16.68M ≈ 7.51× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 125.23M USD | Assets, Current |
| Current obligations | 16.68M USD | Liabilities, Current |
| Cash and equivalents | 35.77M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 80.57M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.61M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $125.23M | $16.68M | $35.77M | $80.57M | (m) | (m) | $1.61M | (m) | 7.51× |
| 2026-03-31 | $146.98M | $17.45M | $43.31M | $98.17M | (m) | (m) | $2.72M | (m) | 8.42× |
| 2025-12-31 | $202.69M | $26.54M | $65.30M | $131.15M | (m) | (m) | $5.01M | (m) | 7.64× |
| 2025-09-30 | $219.59M | $35.49M | $45.13M | $163.81M | (m) | (m) | $2.12M | (m) | 6.19× |
| 2025-06-30 | $227.89M | $41.98M | $43.94M | $171.65M | (m) | (m) | $1.80M | (m) | 5.43× |
| 2025-03-31 | $245.21M | $40.21M | $74.75M | $161.26M | (m) | (m) | $2.63M | (m) | 6.10× |
| 2024-12-31 | $276.81M | $49.79M | $71.37M | $195.32M | (m) | (m) | $4.00M | (m) | 5.56× |
| 2024-09-30 | $373.44M | $44.21M | $112.53M | $232.84M | (m) | (m) | $3.16M | (m) | 8.45× |
| 2024-06-30 | $381.57M | $40.13M | $76.13M | $294.89M | (m) | (m) | $2.60M | (m) | 9.51× |
| 2024-03-31 | $409.14M | $72.55M | $143.08M | $256.49M | (m) | (m) | $7.58M | (m) | 5.64× |
| 2023-12-31 | $319.68M | $64.51M | $68.80M | $162.07M | (m) | (m) | $1.60M | (m) | 4.96× |
| 2023-09-30 | $261.93M | $61.69M | $65.27M | $187.67M | (m) | (m) | $3.27M | (m) | 4.25× |
| 2023-06-30 | $282.18M | $45.40M | $244.29M | $28.45M | (m) | (m) | $1.66M | (m) | 6.22× |
| 2023-03-31 | $302.63M | $19.94M | $268.32M | $4.99M | (m) | (m) | $3.70M | (m) | 15.18× |
| 2022-12-31 | $124.50M | $72.59M | $98.96M | $19.89M | (m) | (m) | $2.57M | (m) | 1.72× |
| 2022-09-30 | $146.94M | $73.24M | $96.86M | $34.78M | (m) | (m) | $1.34M | (m) | 2.01× |
| 2022-06-30 | $151.63M | $97.93M | $78.33M | $69.73M | (m) | (m) | $1.22M | (m) | 1.55× |
| 2022-03-31 | $170.65M | $101.68M | $131.87M | $34.96M | (m) | (m) | $1.20M | (m) | 1.68× |
| 2021-12-31 | $136.70M | $50.98M | $117.43M | $15.11M | (m) | (m) | $574.00K | (m) | 2.68× |
| 2021-09-30 | $126.20M | $26.70M | $111.47M | $10.02M | (m) | (m) | $592.00K | (m) | 4.73× |
| 2021-06-30 | $148.65M | $24.69M | $117.84M | $25.14M | (m) | (m) | $790.00K | (m) | 6.02× |
| 2021-03-31 | $175.84M | $24.75M | $117.80M | $43.71M | (m) | (m) | $3.18M | (m) | 7.10× |
| 2020-12-31 | $197.77M | $26.77M | $104.44M | $76.70M | (m) | (m) | $634.00K | (m) | 7.39× |
| 2020-09-30 | $216.31M | $42.05M | $147.45M | $52.57M | (m) | (m) | $3.39M | (m) | 5.14× |
| 2020-06-30 | $246.66M | $67.53M | $144.32M | $85.35M | (m) | (m) | $2.04M | (m) | 3.65× |
| 2020-03-31 | $272.48M | $72.54M | $165.23M | $85.70M | (m) | (m) | $4.82M | (m) | 3.76× |
| 2019-12-31 | $304.66M | $76.01M | $86.04M | $195.49M | (m) | (m) | $4.07M | (m) | 4.01× |
| 2019-09-30 | $327.60M | $80.17M | $82.64M | $224.76M | (m) | (m) | $4.03M | (m) | 4.09× |
| 2019-06-30 | $340.77M | $69.15M | $79.89M | $247.58M | (m) | (m) | $2.23M | (m) | 4.93× |
| 2019-03-31 | $365.17M | $58.78M | $113.26M | $245.24M | (m) | (m) | $2.26M | (m) | 6.21× |
| 2018-12-31 | $162.48M | $31.67M | $46.86M | $108.95M | (m) | (m) | $1.04M | (m) | 5.13× |
| 2018-09-30 | $182.47M | $30.03M | $42.14M | $137.46M | (m) | (m) | $1.42M | (m) | 6.08× |
| 2018-06-30 | $200.25M | $29.09M | $59.61M | $136.51M | (m) | (m) | $1.56M | (m) | 6.88× |
| 2018-03-31 | $220.63M | $30.94M | $140.37M | $77.83M | (m) | (m) | $1.37M | (m) | 7.13× |
| 2017-12-31 | $171.79M | $15.90M | $31.53M | $137.52M | (m) | (m) | $1.02M | (m) | 10.81× |
| 2017-09-30 | $128.19M | $20.94M | $48.20M | $77.39M | (m) | (m) | $911.00K | (m) | 6.12× |
| 2017-06-30 | $144.73M | $11.84M | $66.30M | $75.02M | (m) | (m) | $307.00K | (m) | 12.23× |
| 2017-03-31 | $161.08M | $11.06M | $43.60M | $114.07M | (m) | (m) | $557.00K | (m) | 14.56× |
| 2016-12-31 | $178.79M | $13.80M | $36.64M | $137.78M | (m) | (m) | $550.00K | (m) | 12.95× |
| 2016-09-30 | $193.02M | $19.39M | $63.51M | $127.65M | (m) | (m) | $787.00K | (m) | 9.96× |
| 2016-06-30 | $205.48M | $19.76M | $67.03M | $136.96M | (m) | (m) | $454.00K | (m) | 10.40× |
| 2016-03-31 | $205.70M | $23.08M | $33.90M | $170.10M | (m) | (m) | $1.70M | (m) | 8.91× |
| 2015-12-31 | $195.89M | $23.93M | $31.31M | $163.03M | (m) | (m) | $612.00K | (m) | 8.19× |
| 2015-09-30 | $108.61M | $23.37M | $66.53M | $41.14M | (m) | (m) | $541.00K | (m) | 4.65× |
| 2014-12-31 | $8.36M | $2.47M | $7.04M | (m) | (m) | (m) | $1.55M | (m) | 3.38× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |